The client needed to evaluate the commercial potential of multiple launch indications, each with varying levels of available evidence. What they had was fragmented. Data on disease burden was sparse, and there was limited clarity on how that aligned with competitive activity, price benchmarks, and patient sentiment. Our task was to bridge these gaps and provide a clearer basis for launch strategy.
We began with a structured review of the existing literature to identify prevalence data across the proposed indications. This was enhanced with forecasting models to estimate future burden and filtered by population variables such as geography and demographics. To contextualise this, we analysed competitor pipelines, approved treatments, and pricing across relevant markets. Our digital intelligence team also ran a listening exercise to understand how competitors were being perceived by patients and clinicians online
We brought everything together in a set of tailored intelligence boards. These made it easy for the client to explore different market scenarios, weigh trade-offs between indications, and pressure-test their assumptions. Alongside the visual tools, we provided strategic recommendations on which launch paths looked most promising, factoring in prevalence, unmet need, likely pricing, and readiness for market.
This wasn’t just about filling a knowledge gap. It gave the client a way to make confident, evidence-led choices in the face of uncertainty. With a clearer view of the landscape, they were able to shape their internal strategy, align stakeholders, and move forward with greater conviction.
Since the initial analysis, we’ve continued to support the team with live epidemiology models and landscape updates. As they refine their messaging and move closer to launch, our tools evolve with them to ensure decisions remain grounded in the most current data.
